PE

Verdantas Appoints Ashraf Jahangir, PE, as Chief Strategy Officer, Strengthening Commitment to its Future Vision

Retrieved on: 
Tuesday, October 31, 2023

Verdantas, a private-equity-backed solution provider of sustainable engineering and environmental services, announced today that Ashraf Jahangir, PE, will join its Executive Leadership team as the new Chief Strategy Officer.

Key Points: 
  • Verdantas, a private-equity-backed solution provider of sustainable engineering and environmental services, announced today that Ashraf Jahangir, PE, will join its Executive Leadership team as the new Chief Strategy Officer.
  • His professional career began in project engineering, operations and client management, evolving into senior leadership and Board governance.
  • Chris Lee, Co-Founder and Managing Partner at RTC Partners, commented, "The appointment of Jahangir as Chief Strategy Officer marks a new chapter in Verdantas' journey.
  • His vision and experience will guide Verdantas towards even greater success as an industry leader."

MoFo Survey: Tech M&A Poised for Upswing; Disruption and Competition Sharpen Focus for Dealmakers

Retrieved on: 
Thursday, November 2, 2023

SAN FRANCISCO, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Morrison Foerster, a leading global law firm, today announced the results of its annual Tech M&A Survey, which reveals that dealmakers anticipate a potential rebound in M&A activity as they look to 2024. While global telecommunications, media, and technology (TMT) M&A transactions dropped by 63% in value terms and 32% by volume in H1 2023 compared to the same period in 2022, TMT deals continued to account for a very sizeable share of global M&A, representing almost a quarter of all M&A transactions globally and demonstrating the adoption of digital transformation and data analytics in every sector. The new Morrison Foerster survey report, "Directing Disruption: AI and Cybersecurity Underline Tech Sector's Flair for Self-Renewal," conducted in conjunction with Mergermarket, also reveals that challenging dealmaking and macroeconomic factors led to tech M&A strategies shifting to securing working capital and focusing on liquidity; adopting alternative deal structures or minority investments; and completing strategic middle market deals to increase competitiveness.

Key Points: 
  • We expect these and other technology areas to have a massive impact on global deal activity in the years to come."
  • New tech subsectors also emerged as targets for future tech M&A transactions in the 2023 survey: cybersecurity (25% of first-choice votes), AI/machine learning (18%), and enterprise/logistics software (16%).
  • The new ESG disclosure and compliance requirements are cropping up globally in parallel to the increased attention from tech M&A dealmakers.
  • In Q2 2023, Mergermarket surveyed 300 dealmakers from around the world to gain insights into the future of technology related M&A.

A new anticoagulant in Pharmascience Canada's portfolio this fall!

Retrieved on: 
Thursday, November 2, 2023

MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.

Key Points: 
  • MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.
  • It helps prevent blood clots from forming by directly blocking the activity of a clotting factor called Factor-Xa.
  • "Pharmascience is proud and committed to serving Canadian patients through the local production of our medications!
  • mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

RAND Launches Building Design Group, Offering Comprehensive Services for Complex Projects

Retrieved on: 
Wednesday, November 1, 2023

NEW YORK, Nov. 1, 2023 /PRNewswire-PRWeb/ -- RAND Engineering & Architecture, a New York City-based firm, is proud to announce the launch of its Building Design Group, a specialized team of experts dedicated to providing comprehensive solutions for complex projects, including adaptive reuse, multi-disciplinary endeavors, gut renovations, and new construction. Led by Principal Peter Varsalona, PE, CEM, CBCP, who brings over 30 years of experience to the team, and Director of Design & Project Management Suzanna Takayama, RA, RAND's Building Design Group offers a multi-faceted blend of architectural design, structural engineering, MEP systems integration, sustainability solutions, forensic engineering, and project management.

Key Points: 
  • RAND Engineering & Architecture, DPC announces the launch of its Building Design Group, a specialized team of experts dedicated to providing comprehensive solutions for complex projects, including adaptive reuse, multi-disciplinary endeavors, gut renovations, and new construction.
  • NEW YORK, Nov. 1, 2023 /PRNewswire-PRWeb/ -- RAND Engineering & Architecture, a New York City-based firm, is proud to announce the launch of its Building Design Group, a specialized team of experts dedicated to providing comprehensive solutions for complex projects, including adaptive reuse, multi-disciplinary endeavors, gut renovations, and new construction.
  • The Building Design Group offers a wide array of services with a particular emphasis on adaptive reuse and multi-disciplinary projects.
  • RAND's services encompassed architectural design, interior design, structural engineering, MEP (Mechanical, Electrical, Plumbing) systems, Special Inspections, and Code and Zoning Compliance.

ConcertAI's TeraRecon Broadens Collaboration with Avicenna.AI to Offer AI-Driven Care Coordination for Pulmonary Embolism and Aortic Disease

Retrieved on: 
Wednesday, November 1, 2023

Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).

Key Points: 
  • Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).
  • This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions.
  • "We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection," said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI.
  • We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond."

Late-Breaking Clinical Trial Results Announced at The VEINS 2023

Retrieved on: 
Monday, October 30, 2023

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • These favorable clinical outcomes highlight the need for randomized controlled trial data comparing MT with standard of care anticoagulation treatment.
  • In the second phase of the trial, 60 participants will be enrolled 1:1 in a dual-blinded, randomized controlled trial (RCT).
  • Of the 21 patients followed at 1 month, 19 (90.5%) had fully compressible and two had partially compressible common femoral veins.

Six Goulston & Storrs Attorneys Named to Lawdragon's 2024 Leading 500 U.S. Dealmakers

Retrieved on: 
Monday, October 30, 2023

Over the past five years alone, he has been lead counsel on more than $3 billion in M&A transactions.

Key Points: 
  • Over the past five years alone, he has been lead counsel on more than $3 billion in M&A transactions.
  • His clients include private and public company sellers, PE firms, strategic acquirers, entrepreneurs, and a broad range of technology companies.
  • Kaden is co-chair of Goulston & Storrs' Corporate Group and serves on numerous firm committees.
  • Sherrier serves on the ABA's Private Target Study Working Group, which publishes the Private Target Mergers & Acquisitions Deal Points Study.

Capital Honda Introduces the 2024 Honda Accord Hybrid to its Inventory: A Fusion of Style, Utility and Performance

Retrieved on: 
Friday, October 27, 2023

CHARLOTTETOWN, PE, Oct. 27, 2023 /PRNewswire-PRWeb/ -- Capital Honda is thrilled to announce the availability of the 2024 Honda Accord Hybrid sedan, a cutting-edge vehicle that blends sophisticated design, practical utility and exceptional performance. This caters to the varied tastes of modern drivers.

Key Points: 
  • Customers who want to buy the new 2024 Honda Accord Hybrid sedan can do so at the Capital Honda dealership.
  • CHARLOTTETOWN, PE, Oct. 27, 2023 /PRNewswire-PRWeb/ -- Capital Honda is thrilled to announce the availability of the 2024 Honda Accord Hybrid sedan, a cutting-edge vehicle that blends sophisticated design, practical utility and exceptional performance.
  • The 2024 Honda Accord Hybrid makes a striking first impression with its sleek and contemporary design.
  • Underneath its refined exterior, the 2024 Honda Accord Hybrid boasts an innovative hybrid powertrain that delivers impressive performance and unmatched fuel efficiency.

Hagens Berman: Kenvue, Inc. (KVUE) Accused of Not Disclosing Known Commercial Risks to Cold Medicine Drugs Firm Encourages Kenvue (KVUE) Investors with Substantial Losses to Contact its Attorneys

Retrieved on: 
Thursday, October 26, 2023

SAN FRANCISCO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Kenvue, Inc. (NYSE: KVUE) investors who invested in Kenvue shares pursuant or traceable to Kenvue’s May 2023 initial public offering and who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Kenvue, Inc. (NYSE: KVUE) investors who invested in Kenvue shares pursuant or traceable to Kenvue’s May 2023 initial public offering and who suffered substantial losses to submit your losses now .
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

UZ Brussel PERT and Aidoc Pave the Way as First Hospital in Europe for Expedited Treatment of Pulmonary Embolism with AI

Retrieved on: 
Thursday, October 26, 2023

LONDON, Oct. 26, 2023 /PRNewswire/ -- Aidoc today announced a pioneering collaboration with the Pulmonary Embolism Response Team (PERT) at UZ Brussel (UZB), becoming the first European hospital to use AI for cross-departmental care coordination, expediting treatment for suspected pulmonary embolism (PE) patients. Aidoc automatically flags suspected positive cases of PE and sends an automatic alert to UZ Brussel's Pulmonary Embolism Response Team (PERT), allowing for fast multidisciplinary decision-making and rapid delivery of life-saving treatment.

Key Points: 
  • Aidoc automatically flags suspected positive cases of PE and sends an automatic alert to UZ Brussel's Pulmonary Embolism Response Team (PERT), allowing for fast multidisciplinary decision-making and rapid delivery of life-saving treatment.
  • Pulmonary embolism is the third most common acute cardiovascular syndrome, resulting from a blood clot obstructing a lung artery, and can be swiftly fatal without prompt diagnosis and treatment.
  • "We are thrilled about our ongoing collaboration with Aidoc," states Marc Noppen, CEO of UZ Brussel.
  • "This innovative approach not only enhances patient care but also sets the stage for a promising future of AI-driven healthcare across Europe."